Tilray | TRLY - Current Liabilities


Tilray reported $259.32M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acasti Pharma USD 1.24M 1.08M Sep/2025
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Aurora Cannabis CAD 145.94M 21.82M Dec/2025
Avita Medical AUD 62.68M 77K Dec/2025
Canopy Growth CAD 98.29M 17.19M Dec/2025
Cronos Group USD 42.42M 5.77M Mar/2026
Dianthus Therapeutics USD 38.28M 7.55M Mar/2026
Divis Laboratories Ltd INR 20.43B 3.15B Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
IQVIA Holdings USD 8.33B 9M Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Moderna USD 2.4B 408M Mar/2026
Organigram Holdings CAD 94.05M 32.11M Dec/2025
Organon & Co USD 2.5B 110M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Tilray USD 259.32M 8.32M Sep/2025
Viatris USD 6.81B 284M Mar/2026
Xeris Pharmaceuticals USD 118.59M 9.02M Mar/2026
Zealand Pharma A/S 664.96M 513.61M Dec/2025